{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T21:33:29Z","timestamp":1779226409416,"version":"3.51.4"},"reference-count":33,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"UK Foreign Commonwealth and Development Office","award":["SHAPE, 3DSHAPE"],"award-info":[{"award-number":["SHAPE, 3DSHAPE"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,11,8]]},"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Given limited data on factors associated with hepatitis C virus (HCV) treatment discontinuation and failure in low- and middle-income countries, we aimed to describe patient populations treated for HCV in five countries and identify patient groups that may need additional support.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort analysis using routinely collected data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Public sector HCV treatment programmes in India (Punjab), Indonesia, Myanmar, Nigeria (Nasarawa) and Vietnam.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>104\u2009957 patients who initiated treatment in 2016\u20132022 (89% from Punjab).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary outcomes<\/jats:title>\n                    <jats:p>Treatment completion and cure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patient characteristics and factors associated with outcomes varied across countries and facilities. Across all patients, median age was 40 years (IQR: 29\u201352), 30.6% were female, 7.0% reported a history of injecting drugs, 18.2% were cirrhotic and 4.9% were coinfected with HIV. 79.8% were prescribed sofosbuvir+daclastasvir. Of patients with adequate follow-up, 90.6% (89,551) completed treatment. 77.5% (69,426) of those who completed treatment also completed sustained virological testing at 12 weeks (SVR12), and of those, 92.6% (64 305) were cured. In multivariable-adjusted models, in most countries, significantly lower treatment completion was observed among patients on 24-week regimens (vs 12-week regimens) and those initiated in later years of the programme. In several countries, males, younger patients &lt;20 years and certain groups of cirrhotic patients were less likely to complete treatment or be cured. In Punjab, treatment completion was also lower in those with a family history of HCV and people who inject drugs (PWID); in other countries, outcomes were comparable for PWID.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>High proportions of patients completed treatment and were cured across patient groups and countries. SVR12 follow-up could be strengthened. Males, younger people and those with decompensated cirrhosis on longer regimens may require additional support to complete treatment and achieve cure. Adequate programme financing, minimal user fees and implementation of evidence-based policies will be critical to close gaps.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-062745","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T10:23:45Z","timestamp":1670235825000},"page":"e062745","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Patient outcomes in public sector hepatitis C treatment programmes: a retrospective cohort analysis across five low- and middle-income countries"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1939-1307","authenticated-orcid":false,"given":"Caroline E","family":"Boeke","sequence":"first","affiliation":[{"name":"Clinton Health Access Initiative, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clement","family":"Adesigbin","sequence":"additional","affiliation":[{"name":"National AIDS\/STIs Control Programme, Federal Ministry of Health, Abuja, FCT, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olayinka","family":"Adisa","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Abuja, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chukwuemeka","family":"Agwuocha","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Abuja, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad-Mujtaba","family":"Akanmu","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Abuja, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atiek","family":"Anartati","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Jakarta, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khin Sanda","family":"Aung","sequence":"additional","affiliation":[{"name":"National Hepatitis Control Program, Department of Public Health, Ministry of Health, Naypyidaw, Myanmar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Azania","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Bello Nabe","sequence":"additional","affiliation":[{"name":"Nasarawa State AIDS Control Agency, Nasarawa, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arief","family":"Budiman","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Jakarta, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhui","family":"Chan","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umesh","family":"Chawla","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Fatchanuraliyah","sequence":"additional","affiliation":[{"name":"Directorate of Communicable Disease Prevention and Control, Ministry of Health of the Republic of Indonesia, Jakarta, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oriel","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gagandeep Singh","family":"Grover","sequence":"additional","affiliation":[{"name":"State Viral Hepatitis Management Unit, Department of Health and Family Welfare, Government of Punjab, Chandigarh, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thandar Su","family":"Naing","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Yangon, Myanmar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dang","family":"Ngo","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Hanoi, Viet Nam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian B","family":"Ramers","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Regan","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddharth","family":"Sindhwani","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gertrudis","family":"Tandy","sequence":"additional","affiliation":[{"name":"Directorate of Communicable Disease Prevention and Control, Ministry of Health of the Republic of Indonesia, Jakarta, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khin","family":"Tint","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Yangon, Myanmar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinh Van","family":"Nguyen","sequence":"additional","affiliation":[{"name":"National Hospital of Tropical Diseases, Hanoi, Viet Nam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Witschi","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"McClure","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,12,5]]},"reference":[{"key":"2025121408443347000_12.12.e062745.1","unstructured":"HCV market intelligence report 2021 and preliminary HBV market insights. Clinton health access initiative 2021, 2021. Available: https:\/\/chai19.wpenginepowered.com\/wp-content\/uploads\/2021\/08\/Hepatitis-C-Market-Report_2021-FINAL-1.pdf"},{"key":"2025121408443347000_12.12.e062745.2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2020-003767"},{"key":"2025121408443347000_12.12.e062745.3","unstructured":"Global progress report on HIV . Viral hepatitis and sexually transmitted infections, 2021. Geneva: World Health Organization, 2021."},{"key":"2025121408443347000_12.12.e062745.4","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13399"},{"key":"2025121408443347000_12.12.e062745.5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1590\/s1518-8787.2017051006468","article-title":"Hepatitis C among blood donors: cascade of care and predictors of loss to follow-up","volume":"51","author":"Machado","year":"2017","journal-title":"Rev Saude Publica"},{"key":"2025121408443347000_12.12.e062745.6","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/liv.14469","article-title":"Frequent loss to follow-up after diagnosis of hepatitis C virus infection: a barrier towards the elimination of hepatitis C virus","volume":"40","author":"Aleman","year":"2020","journal-title":"Liver Int"},{"key":"2025121408443347000_12.12.e062745.7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/jvh.13228","article-title":"Loss to follow-up: a significant barrier in the treatment cascade with direct-acting therapies","volume":"27","author":"Darvishian","year":"2020","journal-title":"J Viral Hepat"},{"key":"2025121408443347000_12.12.e062745.8","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.socscimed.2012.02.046","article-title":"Is travel-time to a specialist centre a risk factor for non-referral, non-attendance and loss to follow-up among patients with hepatitis C (HCV) infection?","volume":"75","author":"Astell-Burt","year":"2012","journal-title":"Soc Sci Med"},{"key":"2025121408443347000_12.12.e062745.9","first-page":"296","article-title":"Effectiveness of 12 week ledipasvir\/sofosbuvir and predictors of treatment failure in patients with hepatitis C","volume":"32","author":"Del Rio-Valencia","year":"2019","journal-title":"Rev Esp Quimioter"},{"key":"2025121408443347000_12.12.e062745.10","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.3892\/mmr.2017.6351","article-title":"Viral and host factors associated with outcomes of hepatitis C virus infection (review)","volume":"15","author":"Yan","year":"2017","journal-title":"Mol Med Rep"},{"key":"2025121408443347000_12.12.e062745.11","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J Hepatol"},{"key":"2025121408443347000_12.12.e062745.12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.27892","article-title":"Difficult-to-cure populations with chronic hepatitis C: vanishing in the direct-acting antiviral era?","volume":"62","author":"Terrault","year":"2015","journal-title":"Hepatology"},{"key":"2025121408443347000_12.12.e062745.13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jcv.2015.08.001","article-title":"Rate and predictors of serum HCV-RNA >6 million IU\/mL in patients with chronic hepatitis C","volume":"71","author":"Barreiro","year":"2015","journal-title":"J Clin Virol"},{"key":"2025121408443347000_12.12.e062745.14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1517\/14656566.2016.1112790","article-title":"New hepatitis C therapies for special patient populations","volume":"17","author":"Soriano","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"2025121408443347000_12.12.e062745.15","unstructured":"World Health Organization . Guidelines for the care and treatment of persons diagnosed with chronic HCV infection. Geneva, Switzerland, 2018."},{"key":"2025121408443347000_12.12.e062745.16","unstructured":"Ministry of health, Vietnam. guidelines for diagnosis and treatment of hepatitis C virus. Vietnam, 2021 https:\/\/trungtamytehocmon.medinet.gov.vn\/van-ban\/quyet-dinh-so-2065qd-byt-ngay-29-thang-4-nam-2021-cua-bo-y-te-ve-viec-ban-hanh-vbct13666-44154.aspx"},{"key":"2025121408443347000_12.12.e062745.17","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/QAD.0000000000002523","article-title":"Risk factors for loss to follow-up from antiretroviral therapy programmes in low-income and middle-income countries","volume":"34","author":"Frijters","year":"2020","journal-title":"AIDS"},{"key":"2025121408443347000_12.12.e062745.18","first-page":"1097","article-title":"Antiretroviral therapy enrollment characteristics and outcomes among HIV-infected adolescents and young adults compared with older adults--seven African countries, 2004-2013","volume":"63","author":"Auld","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025121408443347000_12.12.e062745.19","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jiph.2016.06.012","article-title":"Magnitude and causes of loss to follow-up among patients with viral hepatitis at a tertiary care hospital in Saudi Arabia","volume":"10","author":"Balkhy","year":"2017","journal-title":"J Infect Public Health"},{"key":"2025121408443347000_12.12.e062745.20","unstructured":"World Health Organization; . Updated recommendations on simplified service delivery and diagnostics for hepatitis C infection. Geneva, Switzerland, 2022."},{"key":"2025121408443347000_12.12.e062745.21","doi-asserted-by":"crossref","first-page":"874","DOI":"10.5604\/01.3001.0010.5277","article-title":"Direct-Acting antiviral therapy outcomes in Canadian chronic hepatitis C telemedicine patients","volume":"16","author":"Cooper","year":"2017","journal-title":"Ann Hepatol"},{"key":"2025121408443347000_12.12.e062745.22","first-page":"624","article-title":"Chronic viral hepatitis C micro-elimination program using telemedicine. The Mexican experience","volume":"113","author":"P\u00e9rez Hern\u00e1ndez","year":"2021","journal-title":"Rev Esp Enferm Dig"},{"key":"2025121408443347000_12.12.e062745.23","doi-asserted-by":"crossref","first-page":"447","DOI":"10.5152\/tjg.2015.159000","article-title":"Show me ECHO-Hepatitis C: a telemedicine mentoring program for patients with hepatitis C in underserved and rural areas in Missouri as a model in developing countries","volume":"26","author":"Tahan","year":"2015","journal-title":"Turk J Gastroenterol"},{"key":"2025121408443347000_12.12.e062745.24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S2468-1253(21)00012-1","article-title":"Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system","volume":"6","author":"Zhang","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025121408443347000_12.12.e062745.25","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/jvh.13311","article-title":"High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia","volume":"27","author":"Zhang","year":"2020","journal-title":"J Viral Hepat"},{"key":"2025121408443347000_12.12.e062745.26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(21)00397-6","article-title":"A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial","volume":"7","author":"Solomon","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025121408443347000_12.12.e062745.27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229143","article-title":"Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: a systematic review with meta-analysis","volume":"15","author":"Castro","year":"2020","journal-title":"PLoS One"},{"key":"2025121408443347000_12.12.e062745.28","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2214-109X(20)30505-2","article-title":"Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis","volume":"9","author":"Oru","year":"2021","journal-title":"Lancet Glob Health"},{"key":"2025121408443347000_12.12.e062745.29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.7309\/jmtm.6.1.2","article-title":"Meta-Analysis of mobile phone reminders on HIV patients' retention to care","volume":"6","author":"Jong","year":"2017","journal-title":"J Mob Technol Med"},{"key":"2025121408443347000_12.12.e062745.30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208814","article-title":"Supportive interventions to improve retention on art in people with HIV in low- and middle-income countries: a systematic review","volume":"13","author":"Penn","year":"2018","journal-title":"PLoS One"},{"key":"2025121408443347000_12.12.e062745.31","doi-asserted-by":"crossref","DOI":"10.2196\/16863","article-title":"Decentralized, community-based hepatitis C point-of-care testing and direct-acting antiviral treatment for people who inject drugs and the general population in Myanmar: protocol for a feasibility study","volume":"9","author":"Draper","year":"2020","journal-title":"JMIR Res Protoc"},{"key":"2025121408443347000_12.12.e062745.32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-039234"},{"key":"2025121408443347000_12.12.e062745.33","first-page":"573","article-title":"HCV and HIV co-infection among people who inject drugs in Vietnam","volume":"5","author":"Thinh","year":"2020","journal-title":"J Health Soc Sci"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-062745","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T16:44:39Z","timestamp":1765730679000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-062745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":33,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,5]]},"published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1136\/bmjopen-2022-062745"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-062745","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}